Rivaroxaban in patients with atrial fibrillation: from ROCKET AF to everyday practice
2017
ABSTRACTIntroduction: Registries and non-interventional studies offer relevant and complementary information to clinical trials, since they have a high external validity.Areas covered: The information regarding the efficacy and safety of rivaroxaban compared with warfarin, or rivaroxaban alone in clinical practice was reviewed in this manuscript. For this purpose, a search on MEDLINE and EMBASE databases was performed. The MEDLINE and EMBASE search included both medical subject headings (MeSH) and keywords including: atrial fibrillation (AF) OR warfarin OR clinical practice OR ROCKET AF AND rivaroxaban. Case reports were not considered.Expert commentary: In ROCKET AF, rivaroxaban was at least as effective as warfarin for the prevention of stroke in patients with nonvalvular AF at high risk of stroke, but, importantly, with a lesser risk of intracranial, critical and fatal bleedings. A number of observational comparative and non-comparative studies, with more than 60,000 patients included treated with riva...
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
73
References
8
Citations
NaN
KQI